Lanfear Dennis M 4

What happened Dennis M. Lanfear, President, CEO and a director of Coherus Oncology (CHRS), participated in a stockholder‑approved option repricing on May 29, 2026. The filing shows matched dispositions to the issuer totaling 3,205,000 option shares and concurrent grants/acquisitions of 3,205,000 repriced options (i.e., old options cancelled and new options issued). The new exercise price for the repriced options is $1.59 per share (approved for options previously priced at or above $5).

Key details

• Transaction date: May 29, 2026; Form 4 filed June 2, 2026 (filed within the SEC two-business-day window).
• Total options exchanged: 3,205,000 shares (multiple lots listed; dispositions match acquisitions).
• New exercise price: $1.59 per share (repricing approved by stockholders).
• Vesting notes: some options are fully vested/exercisable (F1); other options vest monthly at 1/48th beginning Jan 5, 2023 (F2). Repricing is subject to Lanfear remaining in service through May 29, 2027 (F4).
• Post‑transaction beneficial ownership was not specified in the provided transaction lines.
• Transaction type: derivative exchange/repricing — not an open‑market buy or cash sale.

Context This filing documents an option repricing/exchange (old options cancelled and new options issued at a lower strike). For retail investors, this is not an ordinary sale or purchase of stock; it adjusts the economics of previously granted option awards. The filing is factual and timely; it does not, by itself, indicate the insider’s personal trading intent.